Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
Zacks Investment Research | Jul 03, 2019 09:05PM ET
Smith & Nephew (LON:SN) plc (NYSE:SNN) closed its acquisition of Switzerland-based Atracsys Sàrl, the provider of optical tracking technology used in computer-assisted surgery. The deal, initiated in June 2019, is in line with the company’s strategy to invest in cutting-edge technologies, which will help accelerate its presence in the multi-asset digital surgery and robotic ecosystem space.
However, the financial terms of the deal were kept under wraps.
Atracsys Business at a Glance
Atracsys’ portfolio includes open platform optical navigation and robotic tracking components with applications in orthopaedics, neurosurgery, spine and dental.
With this purchase, Atracsys’ fusionTrack 500 optical tracking camera will be a core enabling technology for Smith & Nephew’s next-generation robotics platform that will be commercially released in 2020.
As compared to the existing tracking technology, the fusionTrack 500 system offers better measurement of speed and latency performance that supports reduced procedure time as well as increases accuracy resulting in finer precision surgical tasks like the bone cuts.
Smith & Nephew's M&As Continue
Smith & Nephew is fortifying its footprint through its inorganic growth path. Last month, the company completed its buyout of Brainlab orthopaedic joint reconstruction business. This business provides digital workflow tools starting from pre-operative planning to intraoperative navigation to post-operative evaluation and sharing.
In April, it concluded the acquisitions of regenerative medicine products maker Osiris Therapeutics and Leaf Healthcare, the developer of the unique Leaf Patient Monitoring System.
Earlier, in January, the company culminated the consolidation of CeterixOrthopadics, the developer of NovoStitch Pro, a device for meniscal repair.
Price Performance
In the past three months, shares of the company have outperformed its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.